Altamira Therapeutics Continue Bentrio Clinical Trial for Seasonal Allergic Rhinitis in Australia

October 3, 2022

https://www.globenewswire.com/news-release/2022/10/03/2526870/0/en/Altamira-Therapeutics-Continue-Bentrio-Clinical-Trial-for-Seasonal-Allergic-Rhinitis-in-Australia.html

HAMILTON, BERMUDA , Oct. 03, 2022 (GLOBE NEWSWIRE) — Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that its “NASAR” clinical trial with its BentrioTM nasal spray for seasonal allergic rhinitis (SAR) has resumed the enrollment of study participants in Australia as its pollen season is starting up again.

Read more at globenewswire.com

Related news for (CYTO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.